ENSYSCE BIOSCIENCES, INC.

ENSC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $4.3M $3.5M $1.1M $3.1M $12.3M $194.2K
Accounts Receivable
Inventory
Total Current Assets $7.2M $5.3M $2.3M $5.3M $15.7M $347.9K $1.2M $1.9M
Property, Plant & Equipment $124.1K $151
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $7.5M $5.6M $2.7M $5.9M $16.4M $351.8K $196.5M $204.8M
Liabilities
Accounts Payable $3.3M $1.4M $1.9M $2.9M $301.1K $1.7M $2.8M $429.2K
Total Current Liabilities $4.6M $2.2M $3.3M $9.5M $16.5M $7.0M $2.8M $437.9K
Long-Term Debt
Total Liabilities $4.6M $2.2M $3.4M $9.9M $24.6M $7.0M $17.5M $13.2M
Stockholders' Equity
Retained Earnings $-139.7M $-129.5M $-121.6M $-110.9M $-85.8M $-56.0M $-136.7K $930.6K
Total Stockholders' Equity $3.2M $3.7M $-322.9K $-3.7M $-7.9M $-6.4M $5.0M $5.0M
← Newer Page 1 of 2 Older →